聚ADP核糖聚合酶抑制剂用于卵巢癌治疗的研究进展
发布时间：2018-07-18 21:34
【摘要】：卵巢癌是导致女性死亡的主要癌症之一,死亡率在妇科癌症中居高不下。聚ADP核糖聚合酶(PARP)抑制剂可靶向杀灭同源重组修复缺陷的肿瘤细胞,包括乳腺癌易感基因(BRCA)突变的癌细胞,这种机制被称为协同致死效应。目前已有3个PARP抑制剂被FDA批准用于治疗晚期BRCA突变的卵巢癌。本文旨在阐述PARP抑制剂治疗卵巢癌的作用机制,并对已进入临床试验阶段的PARP抑制剂进行综述,以期为开发新的卵巢癌治疗药物提供参考。
[Abstract]:Ovarian cancer is one of the leading causes of death in women, and mortality is high in gynaecological cancers. Poly (ADP) ribosomal polymerase (PARP) inhibitors can target tumor cells with homologous recombination repair defects, including breast cancer cells with BRCA mutations, a mechanism known as synergistic lethal effect. Three PARP inhibitors have been approved by FDA for the treatment of advanced BRCA mutant ovarian cancer. The purpose of this article is to explain the mechanism of PARP inhibitors in the treatment of ovarian cancer and to review the PARP inhibitors which have entered the clinical trial stage in order to provide a reference for the development of new ovarian cancer therapy drugs.
【作者单位】： 广西医科大学;军事医学科学院毒物药物研究所 抗毒药物与毒理学国家重点实验室;
【基金】：国家“重大新药创制”科技重大专项资助项目(2016ZX09J16104-001)
【分类号】：R979.1
[Abstract]:Ovarian cancer is one of the leading causes of death in women, and mortality is high in gynaecological cancers. Poly (ADP) ribosomal polymerase (PARP) inhibitors can target tumor cells with homologous recombination repair defects, including breast cancer cells with BRCA mutations, a mechanism known as synergistic lethal effect. Three PARP inhibitors have been approved by FDA for the treatment of advanced BRCA mutant ovarian cancer. The purpose of this article is to explain the mechanism of PARP inhibitors in the treatment of ovarian cancer and to review the PARP inhibitors which have entered the clinical trial stage in order to provide a reference for the development of new ovarian cancer therapy drugs.
【作者单位】： 广西医科大学;军事医学科学院毒物药物研究所 抗毒药物与毒理学国家重点实验室;
【基金】：国家“重大新药创制”科技重大专项资助项目(2016ZX09J16104-001)
【分类号】：R979.1
【相似文献】
相关期刊论文 前1条
1 周天，
本文编号：2132838
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2132838.html
最近更新
教材专著
